Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:administeredBy |
oral suspension
injectable solution oral capsule |
| gptkbp:ATCCode |
gptkb:N03AB02
|
| gptkbp:brand |
gptkb:phenytoin
|
| gptkbp:cause |
gptkb:osteomalacia
ataxia hirsutism gingival hyperplasia megaloblastic anemia |
| gptkbp:contraindication |
hypersensitivity to phenytoin
|
| gptkbp:discoveredIn |
1938
|
| gptkbp:eliminationHalfLife |
22 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
Epanutin
|
| gptkbp:interactsWith |
gptkb:beer
gptkb:warfarin gptkb:carbamazepine oral contraceptives |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedAs |
gptkb:Pfizer
|
| gptkbp:mechanismOfAction |
sodium channel blocker
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
D
|
| gptkbp:routeOfAdministration |
oral
intravenous |
| gptkbp:sideEffect |
nausea
rash drowsiness |
| gptkbp:usedFor |
epilepsy
seizure control |
| gptkbp:bfsParent |
gptkb:phenytoin
|
| gptkbp:bfsLayer |
6
|